x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0230148
| Product Information | |
|---|---|
| CAS No. | 41059-79-4 |
| Formula | C39H64O13 |
| Molecular Weight | 740.92 |
| SMILES | CC1CCC2(OC1)OC3CC4C5CCC6CC(CCC6(C)C5CCC4(C)C3C2C)OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O |
| Target | NFkB |
| Product Description | Timosaponin A3 triggers liver injury through inducing ROS generation and suppressing the expression of BA transporters. Timosaponin A3 has selectively cytotoxic for cancer versus normal cells, the selective cytotoxic properties of it could be related to the inhibition of major oncogenic pathways and induction of ER stress. Timosaponin A3 and Sarsasapogenin can inhibit nuclear factor-kB and p38 signaling in TNF-a stimulated BV2 microglia cells, they have the therapeutic potential for various neurodegenerative diseases caused by inflammation. Timosaponin A3 has application for reducing blood sugar and treating type-B diabete. |
| Format & Storage | |
|---|---|
| Purity | > 98% |
| Shipping | Shipped on dry ice. |
| Storage | Powder: -20 °C, 3 years; 4 °C, 2 years In solvent: -80 °C, 6 months; -20 °C, 1 month |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
